Ovipol Clio supp 0.5mg #15

Ovipol Clio instruction

You can buy Ovipol Clio here

Composition

1 suppository contains:
Active ingredient: estriol 500 µg;
Auxiliary substance: semisynthetic glycerides (of "Supppozir" type) - 1999.5 mg.
Packaging - 15 pcs.

pharmachologic effect

Estrogen synthesized in the human body. When it enters the bloodstream, it forms a complex with specific receptors (in the uterus, vagina, urethra, breast, liver, hypothalamus, pituitary gland), stimulates the synthesis of DNA and proteins. It has a selective effect, mainly on the cervix, vagina, vulva, causes an increase in the proliferation of the epithelium of the vagina and cervix, stimulates its blood supply, helps to restore the epithelium during its atrophic changes during the premenopausal and menopause periods, normalizes the pH of the vaginal environment, the vaginal flora, and the microflora of the vagina and menopause, normalizes the pH of the vaginal environment, the microflora of the vagina and menopause, normalizes the pH of the vaginal environment, the vaginal flora, and the microflora of the vagina and menopause, normalizes the pH of the vaginal environment, the vaginal flora, and the microflora of the vagina and menopause; epithelium to infectious and inflammatory processes, affects the quality and quantity of cervical mucus. Impact on the endometrium is insignificant (slight risk of uterine bleeding).
It has a hypolipidemic effect, slightly increases the concentration of beta-lipoproteins in the blood, increases sensitivity to the action of insulin, improves glucose utilization, stimulates the production of liver globulins that link sex hormones, renin, HDL and blood clotting factors. Through participation in the implementation of positive and negative feedback in the hypothalamic-pituitary-ovarian system, estriol can cause moderate central effects; stimulates parasympathicomimetic reactions.

Pharmacokinetics

Absorption is high. The time to reach Cmax in plasma with intravaginal use is 1-2 hours. Binding to plasma albumin is 90%.
The excretion is carried out mainly by the kidneys as metabolites (several hours after ingestion and lasts up to 18 hours), 2% is excreted through the intestines unchanged.

Ovipol Clio, indications for use

    Atrophy of the mucous membrane of the lower urogenital tract due to estrogen deficiency, pre- and postoperative therapy in postmenopausal women with vaginal access surgeries, menopausal syndrome (hot flushes and increased sweating at night, etc.);
    infertility caused by cervical factors;
    dyspareunia, vaginal dryness, itching, frequent urination, mild urinary incontinence;
    diagnosis for unclear results of a vaginal smear on cytology.

Contraindications

Hypersensitivity, thrombosis (venous and arterial), embolism, marked impaired liver function, hormone-dependent tumors of the uterus or mammary glands, uterine bleeding of unknown etiology, otosclerosis, severe itching or cholestatic jaundice, as well as increasing their manifestations during a previous pregnancy or during steroid administration drugs, pregnancy.

Dosage and administration

Intravaginally, at bedtime.
In case of atrophy of the mucous membrane of the lower parts of the urogenital tract, 1 suppository (0.5 mg) is administered daily for the first 2-3 weeks, then gradually reduce the dose, based on the symptoms, 1 suppository (0.5 mg) 2 times a week.
Pre- and postoperative therapy in postmenopausal women - 1 suppository (0.5 mg) for 2 weeks before or after surgery.
As a diagnostic tool - 1 suppository every other day for a week before taking the next smear.
If the next dose of Ovipol Clio was missed, you should take it immediately. However, if it was found only on the day of the next dose, you should continue taking the drug in the usual way, without replenishing the missed dose. Do not use 2 doses on the same day.

Use during pregnancy and lactation

Contraindicated in pregnancy.

Side effects of Ovipol Clio

Possible: itching and irritation at the injection site, tension and tenderness of the mammary glands.
In combination with gestagens: benign and malignant estrogen-dependent tumors (including breast and endometrial cancer), venous thromboembolism (including deep veins of the lower leg and small pelvis, pulmonary veins), myocardial infarction, stroke, gallbladder disease , chloasma, erythema multiforme, erythema nodosum, hemorrhagic purpura, dementia at the onset of HRT in continuous use of Ovipol Clio after 65 years, acyclic bleeding, "breakthrough" bleeding, increased libido.

special instructions

With prolonged treatment with estrogen, systematic medical examinations are indicated. Before the start of treatment and every 6 months of treatment, a thorough general medical and gynecological examination, including an examination of the mammary glands, should be carried out.
Hormone replacement therapy (HRT) in the treatment of menopausal symptoms is recommended to begin only if they adversely affect the patient's quality of life. In all other cases it is necessary to compare the ratio of benefits and risks. At a younger age, the ratio of benefits and risks is more favorable than that of older women. During treatment, it is necessary to inform the doctor about cases of vaginal bleeding, changes in the mammary glands, jaundice, and signs of thromboembolism (for example, painful swelling of the limbs, sudden chest pain, shortness of breath). In all cases, patients require careful examination.
Reasons for immediate discontinuation of therapy:
    jaundice or impaired liver function;
    increased blood pressure;
    the occurrence of migraine-type headache;
    phlebitis.

Tumors

Long-term estrogen monotherapy increases the risk of endometrial hyperplasia or cancer, which is directly proportional to the dose of the drug and the duration of therapy.
The risk of developing breast cancer depends on the duration of HRT, but after a few years (most often 5 years), after cessation of therapy, it returns to normal. On the background of HRT, the density of breast tissue may increase, which complicates its radiological study.
Prolonged estrogen therapy (5–10 years) is also associated with an increased risk of ovarian cancer.
Against the background of the use of sex hormones, benign or malignant tumors of the liver were rarely observed. In some cases, these tumors led to the development of life-threatening intra-abdominal bleeding. If there is pain in the upper abdomen, an enlarged liver or signs of intra-abdominal bleeding, differential diagnosis should take into account the presence of a liver tumor.

Cardiovascular diseases

HRT is associated with an increased risk of venous thromboembolism (VTE) 1.3-3 times and is more likely to occur during the first year of Ovipol Clio than at a later time. All risk factors for VTE should be taken into account, and when prescribing a drug before surgery, it is necessary to carry out VTE prophylaxis, and it is also necessary to temporarily cancel HRT 4-6 weeks before the surgery and resume treatment only after the woman begins to walk.
The risk of ischemic stroke is particularly increased in old age.
In the absence of VTE in history, but in the presence of thrombosis at a young age with immediate relatives, it is recommended to conduct a screening examination for the presence of thrombophilic disorders. If a thrombophilic defect is detected that is not identical to the disease in relatives, or there is a severe defect (for example, an antithrombin, protein S or protein C deficiency, or a combination of these defects), HRT is contraindicated.
Women who receive treatment with anticoagulants, it is necessary to compare the ratio of benefits and risks.
Estrogens can cause fluid retention. Patients with renal or heart failure while receiving HRT should be under the supervision of a physician.

Other states

Estrogens increase the lithogenicity of bile, which increases the susceptibility of some patients to the development of cholelithiasis when using estrogens.
Estrogens are a weak gonadotropin antagonist and do not have significant effects on the endocrine system.
Cognitive function on the background of HRT does not improve. Data were obtained on the increased risk of dementia in women who began taking continuously combined HRT or estrogen monotherapy after 65 years.
If prolactinomas are detected, the patient should be under close medical supervision (including periodic assessment of prolactin concentration).
In women with hereditary factors for angioedema, exogenous estrogens can cause or worsen the symptoms of angioedema.

Influence on ability to drive motor transport and control mechanisms

The effect of the drug Ovipol Clio on the ability to drive vehicles and mechanisms was not identified.

Interaction

Inductors of microsomal oxidation (phenobarbital, carbamazepine, phenytoin, rifampicin, rifabutin, nevirapine, efavirenz) increase estrogen metabolism; powerful inhibitors (ritonavir, nelfinavir) - significantly inhibit metabolism.
Hypericum perforatum drugs can induce estrogen metabolism.
Estriol enhances the action of lipid-lowering agents.
Weakens the effects of male sex hormones, anticoagulants, antidepressants, diuretic, hypotensive, hypoglycemic agents.

Overdose

When intravaginal use of overdose is unlikely.
Symptoms (for occasional ingestion): nausea, vomiting, "withdrawal" bleeding.
Treatment: symptomatic. There is no specific antidote.

Storage conditions

Shelf life - 3 years
In a dry, dark place at a temperature of 2-25 ° C.

Terms of sell

You can buy Ovipol Clio without a prescription.